New England Journal of Medicine· 2021Q1
Diffuse Large B-Cell Lymphoma
- 1,151citations
- Q1SCImago
- 2021year
Short summary
Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive cancer representing 30% of lymphomas, with current standard chemotherapy curing approximately 65% of patients initially and an additional 20-25% with salvage therapy.
AI-generated from the title and abstract; the full text is not read.
Key points
- DLBCL accounts for approximately 30% of all lymphoma diagnoses.
- Standard combination chemotherapy cures about 65% of DLBCL patients initially.
- An additional 20-25% of DLBCL patients can be cured with salvage therapy.
- Ongoing research aims to tailor DLBCL treatments to specific genetic alterations.
AI-generated from the title and abstract; the full text is not read.
Abstract
DLBCL, an aggressive cancer, accounts for about 30% of all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially, with another 20 to 25% cured with salvage therapy. Efforts are ongoing to tailor therapy to particular genetic lesions.
The authors' abstract, as published at the source. New England Journal of Medicine, 2021 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pathology and Forensic Medicine
Pathology and Forensic MedicineMedicine